Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...

Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...

Bank Leumi (TASE: LUMI) led the market today, rising 0.79% on the day's biggest trading turnover. Mizrahi Tefahot Bank rose 0.60%, Bank Hapoalim (TASE: POLI) rose 0.88%, and Israel Discount Bank (TASE ...

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...

As Deckers Outdoor Corporation DECK prepares to announce its third-quarter fiscal 2025 earnings results on Jan. 30 after ...

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

An upstart biopharma firm founded by two former executives at CinCor Pharma – which celebrated a $1.8B exit to AstraZeneca in ...

Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $28.00.

The company will report earnings before the open on Jan. 29 Israel-based pharmaceutical giant Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is preparing for its latest quarterly earnings report, due ...

Few flavors are as comforting as chocolate. If you feel the winter blues creeping up on you, book a class with Kiki's Cocoa's ...